Investor Relations
TrialIntel.AI is on a mission to de-risk and accelerate clinical trial investment using advanced AI. Incorporated in Singapore as TRIALINTEL.AI (PTE. LTD.), UEN: 202527031G, we empower biotech investors, hedge funds, and pharmaceutical strategists with real-time, high-confidence predictions of Phase 3 clinical trial outcomes.
Why We Exist
Clinical trials are one of the riskiest bets in biotech—over 90% fail, and Phase 3 failures cost upwards of $100M each. The current investment due diligence cycle is painfully slow and highly uncertain. Investors need speed, clarity, and confidence. TrialIntel.AI delivers all three.
Our Edge
- Accurate AI Models: Predict trial success using deep clinical data and Bayesian modeling.
- Fast Insights: Get probability reports in minutes—not months.
- Accessible: Designed for investors, no medical degree required.
- Scalable: From solo angel investors to institutional funds.
Business Model
- Starter ($29/month): For individual biotech investors
- Professional ($290/month): For VC firms, funds, and consultants
- Enterprise (Custom): Tailored deployments for pharma and institutional clients
Current Focus
We're starting with Phase 3 prediction—the highest-impact, highest-cost stage of clinical development.
Phase 1 and Phase 2 predictions will follow as we advance our algorithms and integrate omics data.
Our Ask
We are currently raising pre-seed funding to:
- Complete MVP development and launch
- Recruit AI/ML and pharma domain experts
- Accelerate market entry and customer acquisition
Join Us
We believe the future of biotech investment is predictive, fast, and powered by AI. If you're an investor who shares that vision, we’d love to talk.